Predictors of Loss To Follow Up and Mortality Among Children ≤12 Years Receiving Anti Retroviral Therapy during the First Year at a Referral Hospital in Bali
DOI:
https://doi.org/10.53638/phpma.2016.v4.i2.p03Keywords:
Loss to follow up, mortality, paediatric, ART, IndonesiaAbstract
Background and purpose: Many HIV-infected children in Bali have started antiretroviral therapy (ART), but loss to follow up (LTFU) is a continuing concern, and the issue of childhood adherence is more complex compared to adults.
Methods: This was a retrospective study among cohort of 138 HIV+ children on ART in Sanglah General Hospital, Denpasar, Bali from January 2010 to December 2015. Kaplan-Meier analysis was used to describe incidence and median time to LTFU/mortality and Cox Proportional Hazard Model was used to identify predictors. Variables which were analysed were socio-demographic characteristics, birth history, care giver and clinical condition of the children.
Results: Mean age when starting ARV therapy was 3.21 years. About 25% experienced LTFU/death by 9.1 month resulting in an incidence rate of 3.28 per 100 child month. The higher the WHO stage, the higher the risk for LTFU/mortality along with low body weight (AHR=0.90; 95%CI: 0.82-0.99).
Conclusion: Clinical characteristics were found as predictors for LTFU/ mortality among children on ART.
References
UNAIDS. UNAIDS -Indonesia HIV/AIDS estimates (2013) [Internet]. 2013. Available from: http://www.unaids.org/en/regionscountries/countries/indonesia
WHO. HIV/AIDS Fact sheet No360 [Internet]. 2014. Available from: factsheets/fs360/en/
Schilkowsky LB, Portela MC, de Castilho Sa M. Factors associated with HIV/AIDS treatment dropouts in a special care unit in the City of Rio de Janeiro, RJ, Brazil. Rev Bras Epidemoil [Internet]. 2011;14(2):187–97. Available from: http://www.scielo.br/pdf/rbepid/v14n2/en_01.pdf
Blutinger E, Solomon S, Srikrischna A, Thamburaj E, Ganescha A, Solomon S. Dropout from care among HIV-infected patients enrolled in care at a tertiary HIV care center in Chennai, India. AIDS Care [Internet]. 2014;26(12):1500–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25011519
Fenner L, Brinkhof MWG, Keisser O, Weigel R, Cornell M. Early Mortality and Loss to Follow-up in HIV-Infected Children starting Antiretroviral Therapy in Southern Africa. Acquir Immune Defic Syndr [Internet]. 2010;54(5):524–32. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925143/
Sengayi M, Dwane N, Marinda E, Sipambo N, Failie L, Moultuer H. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Glob Heal Action [Internet]. 2013;6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23364098
WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision. Geneva; 2010.
Hansudewechakul R, Sirisanthana V, Kurniati N, Puthanakit T, Lumbiganon P, Saphonn V, et al. Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr [Internet]. 2010;55(4):503–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975064/pdf/nihms237367.pdf
Miller T, Evans S, Orav E, McIntosh K, Winter H. Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr. 1993;57:588–92.
McKinney R, Robertson R, Duke Pedriatric AIDS Clinical Trial Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr. 1993;123:579–82.
Nuetzenadel W. Failure to thrive in childhood. Dtsch Arztebl Int. 2011;108(38):643–9.
Newell M, Coovadia H, M C-B, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236–43.
AIDS INFO Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection [Internet]. 2015. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf
Phelps B, Rakhmanina N. Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges. Paediatr Drugs. 2011;13(3):175–92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Stefanie Juergens, Anak Agung Sagung Sawitri, Ketut Dewi Kumara Wati, I Wayan Gede Artawan Eka Putra, Tuti Parwati Merati
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
**Creative Commons Attribution 4.0 International License (CC BY 4.0)**
*Welcome to the world of open collaboration and shared creativity! The Creative Commons Attribution 4.0 International License (CC BY 4.0) empowers creators to share their work with the world while maintaining certain rights.*
**Key Points:**
1. **Freedom to Share:** CC BY 4.0 allows creators to share their work globally, granting others the freedom to use, remix, and build upon it.
2. **Attribution Requirement:** Users can use the work for any purpose, even commercially, as long as they provide appropriate credit to the original creator.
3. **Flexibility:** Applicable to various content types—text, images, music, videos—the license fosters a diverse range of creations.
**Common Use Cases:**
- **Education:** Widely used for educational materials, promoting open learning environments.
- **Research:** Applied to scholarly articles, accelerating the dissemination of knowledge.
**How to Use:**
1. **Share:** Share your work with the world, marking it with the CC BY 4.0 license.
2. **Attribution:** Users, when utilizing the work, must provide proper attribution to honor the original creator.
**Conclusion:**
CC BY 4.0 contributes to a more open and collaborative digital landscape. Join the movement of shared knowledge and creativity!
*For full license details, visit [Creative Commons](https://creativecommons.org/licenses/by/4.0/).*
